Source MDx Liquidating Assets | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Source Precision Medicine, dba SourceMDx, said today that it has assigned all its assets to Joseph Finn of accounting firm Finn, Warnke & Gayton for liquidation.

Source MDx has gone out of business and its intellectual property and patents will be sold at a sealed bid sale on April 29 at noon. The liquidation is being conducted for the benefits of Source MDx's creditors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.